Cancervax's new drug seems like a hodge-podge cancer vaccine attempt to me... a cross between BIOM's single antigen approach and AGEN's tumour-derived hsp vaccine.
And as is obligatory for vaccine's, their initial phase I/IIs trial were successful, with the old "those who developed an immune response did better than those who didn't" story.
Wonder if history will repeat itself with this drug?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.